Application of dioscin in medicine for treating rheumatoid arthritis and mechanism research method

Through database prediction and mouse model verification, the core targets and treatment mechanism of diosine saponin were clarified, the problem of insufficient target confirmation in the existing technology was solved, the treatment effect of rheumatoid arthritis was improved, and theories were provided for its clinical application. Base.

CN118919098AInactive Publication Date: 2024-11-08YUNNAN UNIVERSITY OF CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410990497.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a lack of a method for determining the exact role target and target confirmation of diosine in rheumatoid arthritis in the prior art, which limits its clinical application, and the current situation of rheumatoid arthritis treatment is not optimistic.

Method used

Through the database, the intersection targets of diosperm and rheumatoid arthritis were predicted, the protein interaction network map was constructed, the core targets were screened, and the gene ontology function and KEGG pathway enrichment analysis was carried out to establish the DBA/1 mouse induced by bovine type II collagen. Arthritis model, drug intervention and pathological injury assessment are carried out to clarify the treatment mechanism of diosine.

Benefits of technology

The core targets and treatment mechanisms of dioxins are quickly and effectively screened out, providing a theoretical basis for its application in rheumatoid articulation drugs, and improving the therapeutic effect and drug quality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118919098A_ABST
    Figure CN118919098A_ABST
Patent Text Reader

Abstract

The invention discloses a research method of an action mechanism of dioscin for treating rheumatoid arthritis. The research method comprises the following steps: acquiring a signal channel of the dioscin related to RA; constructing a bovine type II collagen induced DBA / 1 mouse arthritis (CIA) model, and scoring according to an arthritis clinical scoring method; the method comprises the following steps: randomly dividing mouse arthritis models into a CIA model group, a methotrexate (MTX) positive control group, a low dioscin-L drug delivery group, a medium dioscin-M drug delivery group and a high dioscin-H drug delivery group, and carrying out drug intervention; collecting related data in each control group, including curative effect, pathological injury degree of joint tissue, production level of anti-collagen specific antibody and pro-inflammatory factor IL-17, expression level of lymph node and spleen lymphocyte gamma delta TCR and subtype V delta 4 thereof, and IL-17 + secretion level of gamma delta T cell and subtype V delta 4 thereof; and comparing the collected data of various items of each mouse model to obtain a conclusion of the AR action mechanism of the dioscin. According to the invention, the core target spot can be quickly and effectively screened, the action mechanism can be defined, and the quality of dioscin in medicine application is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical drugs, and specifically relates to an application of dioscin in rheumatoid arthritis drugs and a mechanism research method. Background Art

[0002] Rheumatoid arthritis (RA) is an autoimmune disease with T cell response as the main feature, which is characterized by the infiltration of activated immune cells and the production of inflammatory factors, which can lead to cartilage, bone damage and disability. It is characterized by long-term and difficult to treat, and is a difficult problem in the medical field of the world today. Compared with the normal population, RA patients have a higher risk of serious infection, respiratory diseases, osteoporosis, cardiovascular diseases, cancer and death. The global average prevalence is 0.2%-1.0%, and the prevalence in my country is 0.2%-0.4%. At the same time, the incidence rate in some parts of my country is still on the rise, and the current status of RA treatment in my country is still not optimistic. Therefore, the rising incidence and disability rates have brought huge burdens to patients, medical institutions and society. Actively improving its treatment has great medical significance and social value. Summary of the invention

[0003] In order to further improve the current treatment status of rheumatoid arthritis, the present invention provides an application of dioscin in a rheumatoid arthritis drug and a method for studying the mechanism of action of dioscin in treating rheumatoid arthritis.

[0004] A method for studying the mechanism of action of dioscin in treating rheumatoid arthritis comprises the following steps:

[0005] The intersection targets of dioscin and RA were predicted by database, and the protein interaction network diagram was constructed and visualized by Cytoscape3.7.2 software. The core targets were screened and the gene ontology function (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed to obtain the signaling pathways related to dioscin and RA. The DBA / 1 mouse arthritis (CIA) model induced by bovine type II collagen was constructed. After scoring according to the arthritis clinical scoring method, the mice were randomly divided into CIA model group, methotrexate (MTX) positive control group, dioscin low (Dioscin-L), medium (Dioscin-M), and high (Dioscin-H) administration groups. After drug intervention, the pathological damage degree of joint tissue was analyzed by arthritis clinical scoring method and hematoxylin-eosin (H&E) staining to observe the efficacy of dioscin against collagen arthritis. Enzyme-linked immunosorbent assay (ELISA) was used to analyze the production levels of anti-collagen-specific antibodies and the inflammatory factor IL-17. Flow cytometry was used to detect the expression levels of γδTCR and its subtype Vδ4 in lymph nodes and spleen lymphocytes. Intracellular staining was performed by flow cytometry to detect the secretion of IL-17 by γδT cells and their subtype Vδ4.+ The levels of anti-collagen specific antibodies and inflammatory factor IL-17, the expression levels of γδTCR and its subtype Vδ4 in lymph nodes and spleen lymphocytes, and the secretion of IL-17 by γδT cells and its subtype Vδ4 were compared in the CIA model group, the methotrexate (MTX) positive control group, the dioscin low (Dioscin-L), medium (Dioscin-M), and high (Dioscin-H) administration groups. + The therapeutic mechanism conclusions were drawn at the same level.

[0006] Based on the above, dioscin can be used in therapeutic drugs for rheumatoid arthritis.

[0007] The beneficial effects of the present invention are:

[0008] By adopting different drug intervention methods of multiple control groups (CIA model group, methotrexate (MTX) positive control group, dioscin low (Dioscin-L), medium (Dioscin-M), and high (Dioscin-H) administration groups), the efficacy of different control groups, the degree of pathological damage of joint tissue, the production level of anti-collagen specific antibodies and inflammatory factor IL-17, the expression level of γTCR and its subtype V4 of lymphocytes in lymph nodes and spleen, and the secretion of IL-17 by γδT cells and its subtype Vδ4 + horizontal data for collaborative analysis.

[0009] Dioscin is the main active ingredient of Rhizoma Dioscoreae, but the prior art lacks a clear target and target confirmation method, and thus cannot determine its mechanism of action against rheumatoid arthritis, limiting its clinical application. The method provided by the present invention can quickly and effectively screen core targets and clarify the treatment mechanism, providing a theoretical basis for the actual clinical application of drugs, so as to improve the quality of dioscin in the application of rheumatoid arthritis drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for describing the embodiments are briefly introduced below.

[0011] Figure 1 This is the target map of diosgenin for the treatment of rheumatoid arthritis;

[0012] Figure 2 Dioscin-target-RA diagram;

[0013] Figure 3 PPI network diagram of dioscin in the treatment of RA;

[0014] Figure 4 Diagram of the top 10 key targets of diosgenin in the treatment of RA;

[0015] Figure 5 GO bar chart of diosgenin against rheumatoid arthritis;

[0016] Figure 6 KEGG pathway enrichment analysis diagram of dioscin in the treatment of RA;

[0017] Figure 7 Diagram showing the effects of dioscin on clinical symptoms of collagen arthritis;

[0018] Figure 8 Effects of oral administration of dioscin on clinical symptoms of CIA mice;

[0019] Fig. 9 Effects of oral administration of dioscin on collagen-induced specific immune response and cytokine production;

[0020] Fig.10 Effect of dioscin oral solution administration on the expression levels of γδTCR and its subtype Vδ4 in collagen-induced lymph node and spleen lymphocytes;

[0021] Fig.11 Effect of oral administration of dioscin on the expression of IL-17 in γδT cells and its subtype Vδ4 in lymph node and spleen lymphocytes induced by collagen + Horizontal influence diagram. DETAILED DESCRIPTION

[0022] In order to further explore the therapeutic mechanism of dioscin for rheumatoid arthritis, the present invention provides a method for studying the mechanism of dioscin for treating rheumatoid arthritis, comprising the following steps:

[0023] 1. Screen the core targets of the intersection of diosgenin and RA;

[0024] 2. Based on the screened core targets, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed to obtain the signaling pathways associated with dioscin and RA;

[0025] 3. Construct a bovine type II collagen-induced arthritis (CIA) model in DBA / 1 mice and score it according to the clinical scoring method for arthritis;

[0026] 4. The mouse arthritis model constructed in step 3 above was randomly divided into a CIA model group, a methotrexate (MTX) positive control group, a dioscin low (Dioscin-L), medium (Dioscin-M), and high (Dioscin-H) administration group, and drug intervention was performed;

[0027] 5. Collect relevant data from each control group in step 4, including but not limited to efficacy, pathological damage degree of joint tissue, production level of anti-collagen specific antibodies and inflammatory factor IL-17, expression level of γδTCR and its subtype Vδ4 in lymph nodes and spleen lymphocytes, secretion of IL-17 by γδT cells and its subtype Vδ4 + level;

[0028] 6. Compare the category data collected in step 6 of each mouse model group to draw conclusions on the mechanism of diosgenin in treating RA.

[0029] The present invention will be further described below in conjunction with the embodiments.

[0030] Example 1

[0031] Based on the above mechanism research method, this embodiment provides a preferred screening method for core targets and a preferred implementation method for pathway enrichment analysis, including the following steps:

[0032] Step 1: Predict dioscin targets

[0033] The chemical information of dioscin and its simplified molecular input code (SMILES) were obtained through the PubChem database (https: / / pubchem.ncbi.nlm.nih.gov). Subsequently, this code was used to predict the key biological targets of dioscin based on molecular structure similarity on the SwissTargetPrediction website (http: / / www.swisstargetprediction.ch) and the similarity sequence analysis (SEA) tool (https: / / sea.bkslab.org).

[0034] Step 2: Predict RA targets

[0035] By entering "rheumatoid arthritis" as a keyword in the GeneCards (https: / / www.genecards.org / ) and OMIM (https: / / www.omim.org / ) databases, we found target genes related to RA. We sorted these genes into an Excel spreadsheet, removed duplicate gene information, and merged them to obtain a list of rheumatoid arthritis-related gene targets required for the study.

[0036] In this example: 119 effective targets of dioscin were obtained through pubchem, SwissTargetPrediction, and SEA databases. 6029 targets related to RA were predicted through OMIM and Genecards databases. 75 targets of dioscin and RA intersection were obtained using Venny software. The "dioscin-target-RA" network diagram constructed by Cytoscape3.7.2 has 77 nodes and 150 edges. The results are as follows Figure 1 , Figure 2 shown.

[0037] Step 3: Obtain intersection target

[0038] Venny (https: / / bioinfogp.cnb.csic.es / tools / venny / ) software was used to obtain the intersection targets of diosgenin effective targets and RA-related targets as potential key targets for diosgenin in the treatment of RA.

[0039] Step 4: Constructing protein-protein interaction network

[0040] The intersection targets of dioscin and RA were uploaded to the String database (https: / / string-db.org / ) to generate a PPI network, the condition was set to "Homosapiens", the confidence was set to the highest confidence (score value > 0.9), and the other parameters remained at the default settings. The results were saved as TSV files and imported into Cytoscape3.7.2 software to construct and visualize the target network, and the core targets were obtained by setting the degree value greater than the average value.

[0041] In this example, the obtained dioscin targets and 75 RA-related targets were imported into the String database for protein-protein interaction prediction, thereby constructing a protein-protein interaction network. The network has 51 nodes and 315 edges, of which STAT3, CASP3, JUN, FGF2, GSK3B, MMP2, IL2, HSP90AA1, PDGFRB, and MET are core targets. The results are as follows: Figure 3 , Figure 4 shown.

[0042] Step 5: GO and KEGG pathway enrichment analysis

[0043] The ClusterProfiler, Stringin and Pathview packages were installed and executed in the R environment using Bioconductor (http: / / www.bioconductor.org / ) to perform GO and KEGG functional enrichment analysis on the biological process of dioscin in the treatment of rheumatoid arthritis. The analysis results were graphically displayed using the microbial information platform. GO analysis revealed the role of dioscin in the treatment of RA in terms of gene function from three aspects: biological process, cellular composition and molecular function. KEGG analysis aims to find out the main signal transduction pathways that dioscin affects in the treatment of RA.

[0044] In this example, GO enrichment analysis: the gene targets at the intersection of dioscin and RA were taken, and GO gene function enrichment analysis was performed using R software, and a total of 3015 items related to biological process (BP), 203 items related to cellular component (CC), and 334 items related to molecular function (MF) were screened out; 30 major items of biological function that were significantly enriched in drug treatment of diseases were screened using P < 0.05 as the standard, and the results are as follows: Figure 5 As shown in the figure, biological processes mainly cover the control of biological rhythms, drug responsiveness, regulation of MAP kinase action, promotion of protein serine / threonine kinase activity, tyrosine phosphorylation in peptides, modification of tyrosine peptides, signal transduction through G protein-coupled receptors to activate phospholipase C, and regulation of tyrosine phosphorylation in peptides. Cellular components mainly include the structural parts of synaptic membranes, intrinsic components of synaptic membranes, structural units of postsynaptic membranes, intrinsic elements of postsynaptic membranes, structural elements of glutamatergic synapses and presynaptic membranes. Molecular functions mainly involve the activity of G protein-coupled neurotransmitter receptors, G protein-coupled amine receptor activity, acetylcholine receptor function, postsynaptic neurotransmitter receptor activity, G protein-coupled 5-hydroxytryptamine receptor action, and neurotransmitter receptor function.

[0045] In this example, KEGG pathway enrichment analysis: KEGG pathway enrichment analysis was performed using R software, and a total of 227 pathways related to the treatment of RA with dioscin were enriched. According to P < 0.05, the pathways related to the treatment of RA with dioscin were screened out, namely: IL-17 signaling pathway, PI3K-Akt signaling pathway, Ras signaling pathway, EGFR signaling pathway, MAPK signaling pathway, Rap1 signaling pathway, etc. The results are as follows Figure 6 shown.

[0046] The results of network pharmacology studies showed that the mechanism of action of dioscin against rheumatoid arthritis is related to the IL-17 signaling pathway. The results of this example showed that dioscin could inhibit the production of Th17 cytokines by splenic lymphocytes of collagen-induced arthritis mice, and inhibit the expression of intracellular IL-17 cytokines (CD4+IL-17+) and Th17 cell-related genes in splenic lymphocytes of collagen-induced arthritis mice, which is consistent with the results of this study.

[0047] Example 2

[0048] Based on the above mechanism research method, this embodiment provides a scoring method and process for a bovine type II collagen-induced DBA / 1 mouse arthritis (CIA) model, comprising the following steps:

[0049] 0.1 mol / L acetic acid was added to bovine type II collagen to a concentration of 10 mg / ml, and dissolved in a refrigerator at 4°C 1 day in advance. The collagen was fully emulsified with an equal volume of Freund's complete adjuvant. After male DBA / 1 mice were anesthetized, sensitization was performed at the base of their tails with 25 μL per mouse. Three weeks later, a second immune attack was performed with the same dose to construct a DBA / 1 mouse CIA model.

[0050] The severity of arthritis in the limbs of mice was observed with the naked eye and scored on a scale of 0-4. The total score of the limbs of each group of mice was divided by the number of mice, and the average was taken as the clinical score. The maximum score for each mouse was 16 points. Day 0 was the day of attack. The arthritis scores are shown in Table 1:

[0051] Table 1 Joint scoring criteria

[0052]

[0053] Example 3

[0054] Based on the above Example 2, this example groups the constructed mouse models and collects relevant data for comparison, specifically including the following steps:

[0055] Step 1: Experimental grouping and drug administration

[0056] Eight days after the immune attack of collagen arthritis mice, the model mice were scored and divided into an arthritis pathology model group, a positive control group, and a dioscin intervention group according to their clinical scores, with 8 mice in each group.

[0057] Among them, the arthritis pathology model group and the positive drug MTX administration group received solvent control and MTX2mg / kg treatment respectively; while the three different doses of dioscin high, medium and low were administered by gavage with 50mg / kg, 25mg / kg and 12.5mg / kg of dioscin respectively. All the above administration groups started to be administered after 8 days of attack, once a day, and the administration time was 20 days.

[0058] Step 2: Preparation of splenic lymphocytes

[0059] 20 days after the second immunization, we used the mouse despinsal method to treat the mice in each experimental group. The spleen was taken under sterile conditions and ground with a glass slide. Then we used PBS to rinse twice to remove the residue. After standing for 3 minutes, the supernatant was aspirated into a centrifuge tube and centrifuged at 1200rpm for 5 minutes. The supernatant was discarded and red blood cell lysis buffer was added to prepare a single cell suspension. The resuspension volume was kept at about 1ml in each spleen. The pipette was gently blown to mix, and the mixture was allowed to stand for 1 minute, and the centrifugation step was performed again. After repeating the washing 1-2 times, the remaining cells were washed twice with RPMI-1640 (containing 10% FBS) and adjusted to the desired cell concentration.

[0060] Step 3: Histopathological examination

[0061] After the mice were killed by cervical dislocation, their hind limbs were quickly removed and the surface hair was removed. The hind limbs were washed with 0.9% saline to remove the residual hair on the surface. The cleaned mouse hind limb samples were soaked in a solution containing 10% formalin for two days to stabilize the tissue structure. After fixation, the tissue was decalcified and dried, and then soaked in a clarifier. Finally, the tissue was embedded in paraffin and cut into 5-micron thick sections. After removing the paraffin, these sections were stained with hematoxylin-eosin, dehydrated, transparent and sealed. These sections were observed under a microscope and scored according to the standard histological scoring system for joint tissue, as shown in Table 2:

[0062] Table 2 Joint histology scoring criteria

[0063]

[0064] Step 3: Analyze the production level of anti-collagen specific antibodies and inflammatory factor IL-17 using enzyme-linked immunosorbent assay (ELISA)

[0065] According to the operating instructions of the kit, the capture antibody was diluted with 1×CoatingBufffer, 100 μl was added to each well, and a 96-well plate (CorningCostar9018) was used and stored in a 4°C refrigerator overnight. The antibody solution was removed, the plate was washed 3-5 times according to the instructions of the manual, 250 μl of blocking solution was added to each well, and the blocking was carried out at room temperature for 2 hours. After removing the blocking solution, the plate was washed again 3-5 times, the standard and serum samples were diluted stepwise with the diluent recommended in the manual, 100 μl was added to each well, and then 50 μl of HRP enzyme was added, and incubated at room temperature for 3 hours in the dark. The mixture was discarded, the plate was washed 4 times, 100 μl of matrix solution was added, and incubated at room temperature for 15 minutes, and then 100 μl of stop solution (1MH3PO4 or 2NH2SO4) was added to each well, and the absorbance value was detected at a wavelength of 450 nm using an enzyme reader to calculate the concentration of IgGtotal, IgG3 and IgG1 specific antibodies. IL-17 detection was detected according to the instructions and the above method.

[0066] Step 4: Detect the expression levels of γδTCR and its subtype Vδ4 in lymph nodes and spleen lymphocytes by flow cytometry

[0067] Lymph node cells and spleen lymphocytes of mice in each group were collected and washed twice with PBS containing 1% BSA. According to 1 μL antibody corresponding to 1*106 cells, an appropriate amount of IgG antibody was added to block Fc receptors to exclude nonspecific signals that may be caused by Fc receptors. Subsequently, fluorescently labeled anti-mouse γδTCR and Vδ4 antibodies were added for surface marker staining. After adding antibodies, the cells were mixed by blowing and incubated at room temperature for 30 minutes, and then 1% BSA PBS was added to wash the cells again. After mixing, centrifuged at 500g for 5 minutes, the supernatant was discarded, and the cells were resuspended with loading buffer, filtered with a 100-mesh filter, and detected by flow cytometry. The number of positive cells was recorded, and the detection results were then analyzed using Flowjo software.

[0068] Step 5: Flow cytometry to detect intracellular γδT cells and subtype Vδ4 expressing IL-17 + level

[0069] Intracellular cytokine staining is as follows: Lymph nodes and spleens of mice in each group are taken as described above, and single cell suspensions are prepared. Cell counts are performed, and appropriate amounts of stimulants are added according to the number of cells for stimulation. The stimulants include PMA, Ionomycin, and BFA components. After adding the stimulants, the cells are co-cultured in a 5% CO2 incubator for 4 hours. After incubation, the cells are collected and washed twice with 10% FBS1640 medium, and then subsequent staining is performed according to the above surface staining method, that is, IgG antibodies are added to block FcR, and surface markers γδT and Vδ4 are stained. After surface staining, the cells were fixed with 4% paraformaldehyde solution and incubated at room temperature for 30 minutes. After fixation, the cells were washed with washing solution, centrifuged at 1000g for 5 minutes, and the supernatant was discarded. The membrane permeation solution was added to permeate the cells. The membrane permeation condition was incubated at room temperature for 30 minutes. After incubation, the cells were washed again and an appropriate amount of fluorescently labeled IL-17 antibody was added. The cells were incubated overnight. After washing again, the cells were resuspended and analyzed using a flow cytometer. Figure 6 Shown: the proportion of T cells in lymphocytes (Figure A), the proportion of γδT cells in T cells (Figure B), the proportion of subtype Vδ4 in γδT cells (Figure C), and the expression level of IL-17 by γδT cells (Figure D).

[0070] Step 6: Statistical analysis

[0071] In order to ensure the reliability and accuracy of the research results, scientific and rigorous methods were used to process and analyze the experimental data. First, the mean ± standard deviation was used to represent the overall distribution of the data. Secondly, the research data was analyzed for normality. For the comparison of the difference between the mean values ​​of two groups of data, when the data were normally distributed and the variances were equal, the independent sample t test was used; when the data did not meet these conditions, the paired sample t test was used. When comparing the mean differences between three or more groups of data, one-way analysis of variance was used. For all comparison results, we set P < 0.05 as the significant level. When the P value is less than 0.05, it can be considered that there is a significant difference between two or more groups of data; otherwise, the difference is considered not significant.

[0072] The results are as follows:

[0073] 1. Dioscin reduces the severity of collagen arthritis in mice

[0074] The experimental results are shown in Table 3 and Figure 7 As shown in the results, after dioscin intervention, the clinical score of the dioscin group was significantly lower than that of the model group. The clinical scores of collagen arthritis in the dioscin intervention group were significantly reduced on days 12, 14, 16, and 18, and the differences were statistically significant (P < 0.05 or P < 0.01).

[0075] Table 3 Effects of oral administration of dioscin on clinical symptoms of CIA mice (X±S, n=8)

[0076]

[0077] Note: Compared with the CIA model group, *P<0.05, **P<0.01

[0078] 2. Effect of oral administration of dioscin on pathological damage of joint tissues in CIA mice

[0079] The results are as follows Figure 8 As shown, a collagen-induced arthritis model was constructed. After dioscin drug intervention, the hind limbs were obtained and HE staining was performed to evaluate the degree of joint pathological damage (Figure A, Figure B, Figure C, Figure D, Figure E), and the arthritis pathological index was calculated (Figure F). The results are expressed as mean + SD. Compared with the CIA model group, *P < 0.05, **P < 0.01.

[0080] The experimental mice in the model group showed typical pathological manifestations of arthritis, such as a large number of inflammatory cell infiltration, synovial connective tissue hyperplasia, obvious neovascularization, and destruction of cartilage and bone. After intervention with dioscin and methotrexate, the pathological manifestations of arthritis in the dioscin and methotrexate groups were significantly alleviated compared with those in the model group; compared with the model group, the arthritis pathological scores of the mice in the Dioscin-H, Dioscin-M and MTX groups were lower than those in the model group, and the differences were statistically significant (P < 0.05). The above results suggest that dioscin can significantly inhibit the pathological damage of collagen arthritis and has a good therapeutic effect on RA.

[0081] 3. Effect of oral administration of dioscin on the production of IL-17 factor and specific antibodies in spleen lymphocytes

[0082] In order to further evaluate the effect of dioscin on collagen-induced specific immune response and cytokine production, bovine II collagen antibody was used to stimulate spleen lymphocytes of arthritis mice to induce antigen-specific immune response, and ELISA was used to detect the cell culture supernatant. Fig. 9 As shown, collagen was used to stimulate spleen lymphocytes of arthritis mice in vitro to induce antigen-specific reactions. The cell culture supernatant was detected by ELISA to detect the level of IL-17 production (Figure A), antibody IgG total concentration (Figure B), IgG1 concentration (Figure C), and IgG3 concentration (Figure D). Compared with the model group, *P<0.05, **P<0.01, ***P<0.001.

[0083] After dioscin intervention, the production of IL-17 by mouse splenic lymphocytes was significantly inhibited, and the difference was statistically significant (P < 0.05, P < 0.01 or P < 0.001); the concentrations of specific antibodies IgGtotal, IgG1 and IgG3 were significantly reduced, among which the difference between IgGtotal and IgG3 was statistically significant (P < 0.05).

[0084] 4. Effect of oral administration of dioscin on the expression levels of γδTCR and its subtype Vδ4 in collagen-induced lymph node and spleen lymphocytes

[0085] Flow cytometry results Fig.10 As shown, lymph node cells and spleen lymphocytes in each group were collected, fluorescently labeled anti-mouse γδTCR and Vδ4 antibodies were added, and flow cytometry was used for detection. Model is the model group, n=5 or 4; Dioscin-L is the low-dose dioscin group, n=5 or 4, and the detection results are expressed as mean+SD. Figure A shows the proportion of γδTCR and Vδ4 cells in lymph nodes; Figure B shows the proportion of γδTCR cells and Vδ4 cells in spleen lymphocytes. Compared with the model group, the proportions of LN-γδTCR, SP-γδTCR and SP-Vδ4 were significantly reduced after dioscin intervention, and the difference was statistically significant, *P<0.05.

[0086] Compared with the model group, the proportion of γδTCR cells in lymph nodes and splenic lymphocytes in the Dioscin-L intervention group decreased significantly (P < 0.05); the proportion of γδT cell subtype Vδ4 cells in splenic lymphocytes decreased significantly (P < 0.05), and it also showed a downward trend in lymph nodes (P = 0.22). The above results indicate that dioscin can specifically inhibit the expression level of γδTCR and its subtype Vδ4.

[0087] 5. Effect of oral administration of dioscin on the expression of collagen-induced intracellular γδT cells and subtype Vδ4 in lymph nodes and spleen lymphocytes on IL-17 + Effect of expression level

[0088] Previous studies have shown that dioscin can inhibit CD4 + T cells produce IL-17 + In order to clarify whether dioscin intervention can inhibit the secretion of IL-17 by γδT cells and their subtypes, and to reveal the role of dioscin in inhibiting IL-17 + The mechanism of action of γδT cell-mediated treatment of RA. Fig.11As shown, lymph nodes and spleen lymphocytes of each group were collected, IgG antibodies were added, and surface marker staining was performed. Model is the model group, n=5; Dioscin-L is the low-dose dioscin group, n=5, and the test results are expressed as mean+SD. Figure A is the ratio of Vδ4 cells and γδTCR cells expressing IL-17 in lymph nodes; Figure B is the ratio of γδTCR cells and Vδ4 cells expressing IL-17 in spleen lymphocytes. Compared with the model group, the level of IL-17 expressed by LN-Vδ4 was reduced.

[0089] After dioscin intervention, the expression of IL-17 by γδT cell subtype Vδ4 in lymph nodes was inhibited compared with the model, but the difference was not statistically significant (P=0.2424).

[0090] In summary, dioscin has a significant therapeutic effect on collagen-induced arthritis mice. The IL-17 signaling pathway is related to the anti-rheumatoid arthritis effect of dioscin. Its mechanism of action is related to the inhibition of γδT cells and subtype expression, but the treatment of arthritis is mainly through downregulating IL-17 derived from CD4+T cells, rather than IL-17 derived from γδT cells.

Claims

1. A method for studying the mechanism of action of dioscin in treating rheumatoid arthritis, characterized in that: The following steps are involved: S1. Screening of core targets of the intersection of diosgenin and RA; S2. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed based on the screened core targets to obtain the signaling pathways associated with dioscin and RA; S3. Construct a bovine type II collagen-induced arthritis (CIA) model in DBA / 1 mice and score it according to the clinical arthritis scoring method; S4. The clinical scores of the mouse arthritis model constructed in step 3 above were evenly divided into a CIA model group, a methotrexate (MTX) positive control group, a dioscin low (Dioscin-L), a medium delta (Dioscin-M), and a high (Dioscin-H) administration group, and drug intervention was performed; S5. Collect relevant data from each control group in step 4, including but not limited to clinical scores, pathological damage degree of joint tissue, production levels of anti-collagen specific antibodies and inflammatory factor IL-17, expression levels of γδTCR and its subtype Vδ4 in lymph nodes and spleen lymphocytes, and intracellular secretion of IL-17 by γδT cells and its subtype Vδ4. + level; S6. Compare the data of S6 collected from each mouse model group to draw conclusions on the clinical efficacy and mechanism of action of diosgenin in the treatment of rheumatoid arthritis.

2. The method for studying the mechanism of action of dioscin in treating rheumatoid arthritis according to claim 1, characterized in that: In step 1, the intersection targets of dioscin and RA were predicted through the database, and a protein interaction network diagram was constructed. The network was visualized using Cytoscape 3.7.2 software to screen the core targets.

3. The method for studying the mechanism of action of dioscin in treating rheumatoid arthritis according to claim 1, characterized in that: In step 2, pathway enrichment analysis was performed to obtain the signaling pathway associated with dioscin and RA.

4. The method for studying the mechanism of action of dioscin in treating rheumatoid arthritis according to claim 1, characterized in that: In S4, the arthritis clinical scoring method is used to evaluate the efficacy of dioscin in preventing collagen arthritis.

5. The method for studying the mechanism of action of dioscin in treating rheumatoid arthritis according to claim 1, characterized in that: In the S4, hematoxylin-eosin (H&E) staining and joint histology scoring were used to evaluate the pathological damage of joint tissue and the efficacy of dioscin in treating RA.

6. The method for studying the mechanism of action of dioscin in treating rheumatoid arthritis according to claim 1, characterized in that: In the S4, enzyme-linked immunosorbent assay (ELISA) was used to analyze the concentration of anti-collagen specific antibodies and the production level of the inflammatory factor IL-17 to evaluate the efficacy of dioscin in treating RA.

7. The method for studying the mechanism of action of dioscin in treating rheumatoid arthritis according to claim 1, characterized in that: In the S4, flow cytometry was used to detect the expression levels of γδTCR and its subtype Vδ4 in lymph node and spleen lymphocytes.

8. The method for studying the mechanism of action of dioscin in treating rheumatoid arthritis according to claim 1, characterized in that: In the S4, intracellular staining was performed by flow cytometry to detect the secretion of IL-17 by γδT cells and its subtype Vδ4 + level.

9. Application of dioscin in drugs for the treatment of rheumatoid arthritis.